论文部分内容阅读
原研药行业作为一项投资期较长、收益期较短的产业,业内企业一直以来都在通过各种方式试图将其专利利益最大化。原研药企业通过与仿制药企业订立反向支付协议的方式,延长了其专利药的收益期间,增进了企业效益。在此方面,美国由于近年来针对多起反向支付协议案件展开了调查和审判,具有丰富的经验。
The original research and pharmaceutical industry as a long-term investment, income shorter period of industry, industry companies have been trying to maximize its patent through various means. The original research and medicine enterprises through the reverse medicine and pharmaceutical companies to enter into a reverse payment agreement, extend the period of its patent medicine income, enhance business efficiency. In this regard, the United States has extensive experience in investigating and adjudicating numerous counter-payment agreements in recent years.